Privia Health Group, Inc.
NASDAQ:PRVAMedical - Healthcare Information Services
+$0.15 today
- Market cap
- $3.14B
- Beta
- 0.87
- P/E (TTM)
- 134.4
- EPS (TTM)
- $0.18
Volume 2.38M
Average 0.95M
PRVA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Privia Health Group, Inc.NASDAQ: PRVA
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $9.05M rose 175.2% year over year, ahead of the +71.4% change in trailing-twelve-month net income. Sequentially, it rose 195.3% from the prior quarter.
Context
- Net income amounted to 1.1% of revenue in FY2025, up 0.3 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of $38.01M (+65.8%) for the fiscal year ending Dec 2026, a step up from the +59.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $9.05M+195.3% QoQ
- Last fiscal yearDec 2025
- $22.92M+59.3% YoY
- LTMJun 2026
- $28.12M+71.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +175.2% | +75.0% | -100.2 pp |
| 1 year | +59.3% | +65.8% | +6.5 pp |
| 3-year CAGR | — | +54.8% | — |
| 5-year CAGR | +38.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 22.92M USD
- Year-over-year change
- +59.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.92M | +59.3% |
| FY2024 | 2024-12-31 | 14.39M | -37.7% |
| FY2023 | 2023-12-31 | 23.08M | +291.3% |
| FY2022 | 2022-12-31 | (12.06M) | +93.7% |
| FY2021 | 2021-12-31 | (190.65M) | — |
Net Income vs competitors
How PRVA compares with its peers on the latest reported figures
- PRVA's LTM Jun 2026 net income of $28.12M is the 7th largest of the 10 companies compared; the peer median is $86.67M.
- Its year-over-year change of +71.4% is the 4th highest of 10, against a peer median of -2.7%.
- Net income amounts to 1.2% of revenue for PRVA, versus a peer median of 7.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $527.72M | +384.3% | +211.5% | 27.9% | |
| LTM Mar 2026 | $354.54M | +41.1% | +54.1% | 6.1% | |
| LTM Mar 2026 | $265.26M | +265.1% | +9.0% | 87.7% | |
| LTM Mar 2026 | $171.15M | -83.1% | -75.5% | 6.8% | |
| LTM Mar 2026 | $86.67M | -44.1% | -29.4% | 36.5% | |
| LTM Mar 2026 | $32.29M | -26.6% | -19.3% | 0.9% | |
| LTM Jun 2026 | $28.12M | +71.4% | — | 1.2% | |
| LTM Mar 2026 | $24.24M | -35.6% | -43.9% | 8.6% | |
| LTM Apr 2026 | $10.19M | +123.9% | — | 2.1% | |
| LTM Mar 2026 | $9.77M | -2.7% | +25.7% | 7.9% | |
| Peer median (excluding PRVA) | $86.67M | -2.7% | -5.1% | 7.9% | |
Competitors are the stored peer set for PRVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (190.65M) | (12.06M) | 23.08M | 14.39M | 22.92M |
| Depreciation & Amortization | 2.46M | 4.57M | 6.53M | 7.27M | 9.91M |
| Deferred Income Tax | (28.41M) | (7M) | 7.47M | 8.82M | 10.87M |
| Stock-Based Compensation | 253.53M | 67.36M | 0 | 0 | 0 |
| Change in Working Capital | 17.97M | (6.35M) | 8.66M | 19.47M | 44.29M |
| Accounts Receivables | (14.64M) | (72.2M) | (96.88M) | (19.82M) | (36.67M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 6.85M | 118.36M | 52.85M | 14.82M |
| Other Working Capital | 32.61M | 59M | (12.82M) | (13.55M) | 66.14M |
| Other Non-Cash Items | 157K | 687K | 35.05M | 59.34M | 75.42M |
| Operating Cash Flow | 55.06M | 47.2M | 80.79M | 109.28M | 163.4M |
| Capital Expenditures | (547K) | (104K) | (113K) | (5.02M) | (1.2M) |
| Acquisitions (Net) | (32.23M) | 125K | (47.89M) | (5.3M) | (181.72M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (125K) | 0 | 0 | 1.35M |
| Investing Cash Flow | (32.78M) | (104K) | (48.01M) | (10.33M) | (181.57M) |
| Debt Repayment | (875K) | (33.25M) | 0 | 0 | (2.46M) |
| Common Stock Issued | 223.69M | 13.45M | 8.74M | 2.68M | 8.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.15M) | 125K | 0 | 0 | 1.11M |
| Financing Cash Flow | 213.66M | (19.68M) | 8.74M | 2.68M | 6.7M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 235.94M | 27.42M | 41.52M | 101.64M | (11.46M) |
| Free Cash Flow | 54.51M | 47.09M | 80.67M | 104.26M | 162.2M |
Privia Health Group, Inc.
NASDAQ:PRVA
Intrinsic Alpha fair value
Locked
Current Price
$24.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.